The new testing system is currently undergoing trials in Cumbria and the North East of England, and health officials plan to extend its availability to the rest of the UK before the end of the year. If successful, it could offer lessons for healthcare systems worldwide, including the United States, where over 37 million adults live with diabetes and millions remain undiagnosed.

How the Test Works

PocDoc’s test is built around the HbA1c marker, widely recognized as the benchmark for identifying and tracking type 2 diabetes. HbA1c measures average blood glucose levels over the past two to three months, offering a reliable picture of long-term sugar control rather than just a single reading. To use the test, patients begin with a simple finger-prick to provide a small blood sample.

The sample is then applied to PocDoc’s patented microfluidic test cartridge, which is designed to capture and process the biomarker. Using the companion smartphone app, the cartridge is scanned, and results are generated in less than 10 minutes, eliminating the need for laboratory analysis.

By shifting screening away from clinics and into homes, pharmacies, and community spaces, the technology reflects a broader trend in digital health—giving individuals greater control and convenience in monitoring chronic conditions such as diabetes.

Why It Matters for Public Health

Type 2 diabetes is one of the most preventable chronic conditions, yet it continues to grow rapidly worldwide. In the UK, around 5.2 million people live with the disease, and another 1.3 million are undiagnosed. Treating diabetes and its complications costs the National Health Service (NHS) about £8.8 billion annually, nearly 10% of its total budget.

In the United States, the challenge is even greater. The Centers for Disease Control and Prevention (CDC) reports that diabetes costs the U.S. healthcare system $327 billion each year, with nearly $1 in every $4 healthcare dollars spent on treating the disease. Alarmingly, 96 million Americans are estimated to have prediabetes, but the majority do not know it.

For both the NHS and U.S. healthcare providers, earlier detection could significantly reduce long-term costs and complications. Lifestyle interventions, such as improved diet, exercise, and weight management, have been shown to reduce the risk of type 2 diabetes by nearly 50% if introduced early.

Professor Julia Newton from Health Innovation Northeast and North Cumbria highlighted this potential: “Type 2 diabetes can often be prevented or even reversed through early detection and lifestyle change. Making tests available at the touch of a button could be a game-changer.”

Implications for U.S. Healthcare

The United States faces unique challenges in managing diabetes. While annual screenings are recommended for high-risk groups, access remains uneven—particularly in rural areas, among uninsured populations, and in communities with limited primary care.

Smartphone-based testing could help bridge these gaps. With more than 85% of U.S. adults owning a smartphone, app-driven diagnostics could reach populations underserved by traditional healthcare. Pharmacies, employer wellness programs, and telehealth providers could integrate rapid HbA1c testing into their services, helping millions access earlier screenings.

That said, scaling such a system in the U.S. would require FDA approval, insurance integration, and careful oversight to ensure accuracy. The FDA has previously flagged risks with some health apps that failed to provide reliable alerts. Ensuring data security and equitable access will also be critical.

Still, experts believe that digital-first models could save billions annually by reducing hospitalizations, dialysis treatments, and cardiovascular emergencies linked to late-diagnosed diabetes.

The Future of At-Home Testing

The diabetes test is not PocDoc’s first foray into digital diagnostics. The company also launched a Healthy Heart Check, an at-home cholesterol and cardiovascular risk screening kit. Its success indicates a broader shift toward self-administered, technology-driven preventive care.

If the diabetes test proves successful in the UK, expansion into other markets could follow. For U.S. patients, this would mean faster access to critical health information and greater control over managing their risk factors.

As healthcare systems worldwide grapple with rising chronic disease costs, tools like the PocDoc test show how technology and preventive medicine can work hand-in-hand. Instead of waiting for symptoms to appear or results to trickle in from distant labs, patients could soon hold answers in the palm of their hand—literally.

[Source]

The post Diabetes Smartphone Test Could Diagnose Condition in Under 10 Minutes appeared first on Medical Journal Daily.

The peer-reviewed paper, published in PAIN, used both careful pain testing and brain imaging to unpack why this works.

What the new study found

Researchers induced sensitization in the nervous system of 30 healthy adults using a standard high-frequency stimulation model, which reliably mimics features of long-term, neuropathic-like pain. Participants then experienced one of three conditions: a 45-minute 360° VR nature session (waterfalls in Oregon), the same footage on a regular 2D screen, or no intervention.

Only the immersive VR condition meaningfully reduced the development and spread of mechanical secondary hyperalgesia (a hallmark of sensitized pain processing), and the benefit persisted through the end of the session. Crucially, relief scaled with “presence”—the stronger the feeling of being in nature, the greater the analgesia.

University summaries note that immersive VR nature was roughly twice as effective as 2D video at reducing pain experience, and that reductions in pain-related sensitivity were still evident at least five minutes after the session. For people who can’t easily access green spaces—like many living with chronic conditions—this matters: VR can deliver a therapeutically rich “dose” of nature on demand.

How it may work in the brain

The researchers also tested brain activity with MRI scans while participants experienced pain from a cold gel. They found that watching nature in VR changed how certain brain regions ‘talked’ to each other. Specifically, it seemed to help the brain’s natural pain-control system kick in, so fewer pain signals spread through the nervous system.

The effect was strongest when people really felt like they were inside the virtual nature scene, which suggests that the sense of presence helps the brain turn down pain more effectively.

The Exeter work builds on a broader line of evidence that nature exposure—virtual or real—tempers pain. Earlier in 2025, a Nature Communications study showed that simply watching well-designed nature videos lowered both reported pain and brain activity tied to pain processing compared with urban or indoor scenes. The authors argued this wasn’t placebo; the brain’s nociceptive (pain-signal) pathways were genuinely less reactive.

VR isn’t a magic bullet, but it is becoming a legitimate tool in multimodal pain management. In 2021, the U.S. FDA authorized the first at-home VR therapeutic for chronic low-back pain—a program grounded in behavioral skills rather than nature content—after randomized trials showed meaningful, durable benefits.

The regulatory milestone signaled that immersive, non-drug approaches can cross the bar for safety and effectiveness. Nature-based VR adds another, potentially complementary, path: it leans on our hard-wired response to natural environments to turn down pain signaling—with minimal side effects.

What this means for people with chronic pain

For clinics, hospitals, and care homes—places where stepping outside isn’t always feasible—curated VR nature sessions could offer accessible, low-risk relief and pair easily with physical therapy, CBT, or medications.

The practical takeaways from the new study are straightforward: aim for immersive, high-quality 360° nature content; run sessions long enough to let presence build (the study used ~45 minutes); and measure outcomes beyond immediate distraction, since benefits persisted.

The PAIN trial simulated chronic-like sensitization in healthy volunteers; it didn’t test people diagnosed with chronic pain, and the sample was small.

We still need large, real-world trials in specific conditions (e.g., neuropathic pain, fibromyalgia), dose-finding work (how often, how long), and comparisons across different natural environments and personalization levels. But taken together with the 2025 neuroimaging results and past VR analgesia research, the case for “virtual nature as therapy” is getting stronger.

[Source]

The post Virtual Reality Nature Scenes Found to Ease Chronic Pain, Study Shows appeared first on Medical Journal Daily.